Physician profile
John Jurige
NPI 1336106301
$7,081.67
in general payments reported to CMS, 2019-2025
23 companies · $248 in 2025
The $248 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $997 · 2021: $506 · 2022: $1,569 · 2023: $1,852 · 2024: $1,499 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,077 · Travel and Lodging: $1,454 · Entertainment: $67.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,077.35 |
| Travel and Lodging | $1,453.93 |
| Entertainment | $67.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $3,125.67 | 2022-2025 | Nanoknife |
| Medtronic, INC. | $1,257.32 | 2021-2025 | Interstim |
| Blue Earth Diagnostics | $819.26 | 2020 | |
| Astellas Pharma US INC | $411.63 | 2019-2023 | Myrbetriq |
| Urogen Pharma, INC. | $394.14 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $175.74 | 2021-2024 | |
| Abbvie INC. | $153.94 | 2022-2024 | |
| Profound Medical Corp. | $125.59 | 2023 | Tulsa-Pro |
| Medtronic USA, INC. | $117.66 | 2019 | |
| Coloplast Corp | $106.67 | 2019 | |
| Sumitomo Pharma America, INC. | $68.42 | 2023-2024 | Orgovyx, Gemtesa |
| Edap Technomed INC | $67.39 | 2025 | |
| Merck Sharp & Dohme LLC | $46.23 | 2020-2023 | Lynparza, Welireg, Keytruda |
| Antares Pharma, INC. | $43.14 | 2020-2022 | |
| Pfizer INC. | $33.21 | 2020-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $24.60 | 2019 | |
| Verity Pharmaceuticals INC. | $23.14 | 2025 | Trelstar |
| Accord Healthcare, INC. | $16.88 | 2022 | |
| Axonics, INC. | $16.07 | 2022 | |
| Ferring Pharmaceuticals INC. | $15.86 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $14.11 | 2019 | |
| Neotract INC. | $13.99 | 2019 | |
| Janssen Biotech, INC. | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Jurige listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.